| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FVT1 |
| Uniprot No | Q06136 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 26-270aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMKPLALPGAHVVVTGGSSGIGKCIAIECYK QGAFITLVARNEDKLLQAKKEIEMHSINDKQVVLCISVDVSQDYNQVENV IKQAQEKLGPVDMLVNCAGMAVSGKFEDLEVSTFERLMSINYLGSVYPSR AVITTMKERRVGRIVFVSSQAGQLGLFGFTAYSASKFAIRGLAEALQMEV KPYNVYITVAYPPDTDTPGFAEENRTKPLETRLISETTSVCKPEQVAKQI VKDAIQGNFNSSLGSD |
| 预测分子量 | 29 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FVT1重组蛋白的模拟参考文献示例(注：以下内容为虚构，仅供格式参考)：
---
1. **文献名称**: *"Expression and Functional Analysis of Recombinant FVT1 Protein in Cancer Cell Lines"*
**作者**: Zhang, L., et al.
**摘要**: 本研究成功在大肠杆菌系统中表达了FVT1重组蛋白，并通过体外实验证实其能够抑制多种肿瘤细胞的增殖。进一步机制研究表明，FVT1通过调控PI3K/AKT信号通路诱导细胞凋亡，提示其作为潜在抗癌治疗靶点的可能性。
---
2. **文献名称**: *"Structural Characterization of FVT1 Recombinant Protein and Its Role in Viral Pathogenesis"*
**作者**: Thompson, R.G., & Kim, S.
**摘要**: 利用X射线晶体学解析了FVT1重组蛋白的三维结构，发现其具有独特的螺旋-折叠复合构象。实验表明，FVT1能与特定病毒包膜蛋白结合，阻断宿主细胞感染过程，为抗病毒药物设计提供了结构基础。
---
3. **文献名称**: *"Development of a Novel FVT1-Based Vaccine Adjuvant and Immunogenicity Evaluation"*
**作者**: Costa, M., et al.
**摘要**: 研究将FVT1重组蛋白作为疫苗佐剂，在小鼠模型中评估其免疫增强效果。结果显示，FVT1可显著提高抗原特异性抗体滴度并激活Th1/Th2混合免疫反应，表明其在疫苗开发中的应用潜力。
---
4. **文献名称**: *"FVT1 Recombinant Protein Attenuates Inflammatory Response in Sepsis Models"*
**作者**: Wang, Y., et al.
**摘要**: 通过动物实验发现，FVT1重组蛋白能有效降低脓毒症模型中的促炎因子(如TNF-α、IL-6)水平，并改善器官损伤。研究提示FVT1可能通过抑制NF-κB通路发挥抗炎作用。
---
**说明**：以上文献为模拟示例，实际研究中请通过学术数据库(如PubMed、Web of Science)以“FVT1 recombinant protein”或相关关键词检索真实文献。若FVT1为特定领域术语，建议补充背景信息以精准查询。
FVT1 recombinant protein is a genetically engineered fusion protein designed for therapeutic or research applications, typically constructed by combining functional domains from distinct proteins to enhance stability, targeting, or biological activity. The "FVT1" designation likely reflects its structural components—potentially an Fc region (for extended serum half-life), a variable domain (for antigen recognition), and a therapeutic payload (e.g., enzyme, cytokine, or toxin). Such proteins are often produced using mammalian expression systems (e.g., CHO cells) or microbial platforms to ensure proper folding and post-translational modifications.
The development of FVT1 aligns with advancements in recombinant DNA technology, enabling precise control over protein design to optimize pharmacokinetics and reduce immunogenicity. Its architecture may leverage modular domains to target specific cell receptors (e.g., cancer biomarkers or immune checkpoints) while delivering conjugated therapeutic effects. Preclinical studies likely focus on validating target binding affinity, functional efficacy in disease models (e.g., oncology, autoimmune disorders), and safety profiles.
FVT1’s applications span targeted therapy, diagnostic tools, and mechanistic studies, reflecting the broader trend of multifunctional biologics in precision medicine. Production involves stringent purification processes (e.g., affinity chromatography) and quality controls to meet regulatory standards. While its exact mechanism remains context-dependent, FVT1 exemplifies the integration of protein engineering to address limitations of conventional therapies, such as off-target effects or short bioavailability. Ongoing research may explore combinatorial regimens or biomarker-driven patient stratification to maximize clinical utility.
×
